Koers Galena Biopharma Inc Nasdaq
Aandelen
US3632565046
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 69,88 mln. 64,6 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -37 mln. -34,2 mln. | Nettowinst (verlies) 2025 * | -38 mln. -35,13 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-1,74
x | K/w-verhouding 2025 * |
-1,98
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,73% |
Recentste transcriptie over Galena Biopharma Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Angelos Stergiou
FOU | Founder | 48 | 03-04-06 |
John Burns
DFI | Director of Finance/CFO | 39 | 01-05-13 |
Andrew Elnatan
LAW | General Counsel | - | 05-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 67 | 29-12-17 | |
David Scheinberg
BRD | Director/Board Member | 68 | 01-12-17 |
John Varian
BRD | Director/Board Member | 64 | 29-12-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+16,61% | 122 mld. | |
+17,75% | 112 mld. | |
+17,23% | 25,91 mld. | |
-24,11% | 19,33 mld. | |
-18,56% | 16,17 mld. | |
-18,47% | 15,6 mld. | |
-47,75% | 14,65 mld. | |
+57,35% | 14,34 mld. | |
+5,62% | 14 mld. |